Lifecore Biomedical, INC \de\ Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
SCHEDULE 13G: BlackRock Discloses 5.1% Stake in LifeCore Biomedical
BlackRock, Inc. has reported a 5.1% beneficial ownership stake in LifeCore Biomedical, Inc., holding 1,899,903 shares of common stock.
NASDAQ
SCHEDULE 13G/A: BlackRock Reports 4.9% Stake in LifeCore Biomedical
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 4.9% beneficial ownership in LifeCore Biomedical, Inc. common stock.
NASDAQ
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.0% beneficial ownership stake in LifeCore Biomedical, Inc.'s common stock.
NASDAQ
Greenhaven Road Investment Management, along with affiliated entities, has reported a 9.8% beneficial ownership stake in Lifecore Biomedical, Inc. as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Greenhaven Road Investment Management Discloses 7.8% Passive Stake in Lifecore Biomedical
Greenhaven Road Investment Management and its affiliated entities have filed an amended Schedule 13G, reporting a passive beneficial ownership of 7.8% in Lifecore Biomedical, Inc.'s common stock as of December 31, 2023.
NASDAQ
David Capital Partners, LLC and David Capital Partners Fund, LP have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.87% in LifeCore Biomedical, Inc. as of December 31, 2024.